Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
McKesson
Mallinckrodt
Federal Trade Commission
McKinsey
Dow
Farmers Insurance
Julphar
Cerilliant

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,145,036

« Back to Dashboard

Which drugs does patent 7,145,036 protect, and when does it expire?

Patent 7,145,036 protects BROVANA and is included in one NDA.

This patent has thirteen patent family members in twelve countries.
Summary for Patent: 7,145,036
Title:Formoterol tartrate polymorph
Abstract:A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Inventor(s): Tanoury; Gerald J. (Hudson, MA), Senanayake; Chris H. (Shrewsbury, MA), Kessler; Donald W. (Groton, MA)
Assignee: Sepracor Inc. (Marlborough, MA)
Application Number:11/052,268
Patent Claim Types:
see list of patent claims
Composition; Process;

Drugs Protected by US Patent 7,145,036

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion BROVANA arformoterol tartrate SOLUTION;INHALATION 021912-001 Oct 6, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,145,036

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,110,706 Formoterol tartrate process and polymorph ➤ Sign Up
7,342,132 Formoterol tartrate process and polymorph ➤ Sign Up
6,472,563 Formoterol tartrate process and polymorph ➤ Sign Up
7,964,753 Formoterol tartrate process and polymorph ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Fish and Richardson
Cerilliant
UBS
Cipla
Cantor Fitzgerald
Teva
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.